Market Overview:
The global radiopharmaceuticals market reached a value of US$ 4.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2027, exhibiting a CAGR of 6.76% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Radiopharmaceuticals are unique formulations comprising radioisotopes that are used in clinical areas for diagnosis and therapy. These medicinal drugs are administered by a radio pharmacist, a medical professional who specializes in nuclear medicine. They are taken in the form of a pill or injected into a vein or cavity of the patient’s body. Once they reach the targeted location, they release radioactive agents to destroy the tumor cells. As a result, radiopharmaceuticals are used to treat thyroid, brain, lymphoma and other types of cancer that have spread to the bones.
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
Radiopharmaceuticals Market Trends:
The increasing prevalence of cancerous diseases on account of the rising aging population and unhealthy dietary patterns represent the key factors contributing to the growing use of radiopharmaceuticals across the globe. Apart from this, the escalating number of diagnostic centers is also supporting the market. Moreover, the rising number of oncologists that are suggesting disease-targeted cancer therapy, which utilizes drugs to target specific proteins and genes involved in the development of cancer cells, are positively influencing the overall sales. Furthermore, the use of radiolabeled peptides and monoclonal antibodies for the diagnosis and treatment of cancerous tumors, along with rising healthcare expenditures, is strengthening the market growth. Other major factors anticipated to propel the growth of the market include the increasing use of radiopharmaceuticals by oncologists to track radioactivity throughout the body and determine the presence of cancer cells and the increasing shift towards positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) scans.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global radiopharmaceuticals market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on product type, application and end use.
Breakup by Product Type:
www.imarcgroup.com
Note: Information in the above chart consists of dummy data and is only shown here for representation purpose. Kindly contact us for the actual market size and trends.
- Diagnostic Nuclear Medicine
- Therapeutic Nuclear Medicine
Breakup by Application:
- Oncology
- Cardiology
- Neurology
- Endocrinology
- Others
Breakup by End Use:
- Hospitals and Clinics
- Research Institutes
- Diagnostic Centers
Breakup by Region:
To get more information on the regional analysis of this market, Request Sample
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2021 |
Historical Period |
2016-2021 |
Forecast Period |
2022-2027 |
Units |
US$ Billion |
Segment Coverage |
Product Type, Application, End Use, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Advanced Accelerator Applications (Novartis AG), Bayer AG, Bracco S.p.A., Cardinal Health Inc., Curium Pharma, General Electric Company, IBA RadioPharma Solutions, Jubilant Pharma Limited, Lantheus Medical Imaging Inc, Nordion Inc. (Sotera Health), NTP Radioisotopes SOC Ltd, PharmaLogic Holdings Corp. and Siemens AG |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |